Closely held PharmaJet has announced that its WHO prequalified Tropis ID delivery system will be used to support a polio eradication campaign sponsored by the National Emergency Operation Center (NEOC) Afghanistan, UNICEF, WHO, and other Global Polio Eradication Initiative (GPEI) partners commencing this month.
Focused on the eastern region of Afghanistan, the campaign will deploy Tropis ID to administer 1.3 million fractional doses of inactivated polio vaccine (fIPV) to children ages five and under in parallel to oral polio vaccine administration as part of a WHO-recommended strategy to boost humoral and mucosal immunity.
PharmaJet has been awarded a UNICEF tender to support WHO and GPEI partners. The use of Tropis ID enables site-to-site immunization, a strategy where vaccination services are offered at multiple, convenient locations. This approach is expected to help increase immunization coverage, particularly in high-risk areas.
In a statement, Paul LaBarre, VP of global business development at PharmaJet, commented, “We are pleased to be partnering with UNICEF, WHO, and NEOC Afghanistan in their continued efforts to eradicate polio. We aim to achieve high impact in the fight against poliovirus, including increased coverage, decreased costs, and high acceptability previously seen with Tropis ID delivered fIPV in Pakistan, Somalia, and Nigeria.”
